Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > OT: mass screening for COVID-19 at work places & venues
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(559)
•••
Comment by chrispion Feb 08, 2021 8:24am
109 Views
Post# 32498655

RE:RE:RE:OT: mass screening for COVID-19 at work places & venues

RE:RE:RE:OT: mass screening for COVID-19 at work places & venuesThat's an interesting question since you have never asked me if I'm buying or selling BTI and I post a lot about it on this board (obviously).
Well, since you asked, I'm a buyer of PMED as their solution for mass detection of COVID-19 for offices/venues/work places is not the reason I initially invested in the company - their cannabis and alcohol impairment technology is. I think they have a unique solution for that space and will do quite well now that cannabis is legal in more and more places throughout the World. The low hanging fruit is detection for the workplace where large #s of workers enter a factory/warehouse/mine site/office building each day.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities